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Abstract The fat-derived protein adiponectin is an important
insulin-sensitizing adipocytokine which is downregulated in in-
sulin resistance and obesity. Recently, two receptors of this
adipose-expressed protein called adiponectin receptor 1 (Adi-
poR1) and 2 (AdipoR2) have been cloned. To clarify expression
and regulation of these receptors in fat cells, AdipoR1 and
AdipoR2 mRNA was measured by quantitative real-time reverse
transcription-polymerase chain reaction during di¡erentiation of
3T3-L1 adipocytes and after treatment with various hormones
known to induce insulin resistance. Interestingly, AdipoR2 syn-
thesis was signi¢cantly increased up to 4.8-fold during di¡er-
entiation of 3T3-L1 preadipocytes, whereas AdipoR1 expression
was only augmented up to 1.4-fold. Furthermore, growth hor-
mone (GH) induced AdipoR2, but not AdipoR1 mRNA by up to
2.4-fold in a dose- and time-dependent fashion with signi¢cant
stimulation detectable at concentrations as low as 5 ng/ml GH
and as early as 2 h after e¡ector addition. The positive e¡ect of
GH on AdipoR2 expression could be reversed by withdrawal of
the hormone for 24 h. In contrast, other key hormones involved
in the regulation of insulin resistance and energy metabolism
such as insulin, isoproterenol, dexamethasone, triiodothyronine,
angiotensin 2, tumor necrosis factor K, and interleukin-6 did not
in£uence AdipoR1 and AdipoR2 synthesis in vitro. Taken to-
gether, our results suggest that AdipoR2 expression is di¡er-
entiation-dependent and selectively regulated by GH implying
a potential role of this hormone in adiponectin-associated alter-
ations of insulin sensitivity and energy homeostasis.
3 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Insulin resistance is frequently associated with obesity and
is a major risk factor for the development of type 2 diabetes,
hypertension, and coronary artery disease. In recent years, the
molecular link between increased adiposity and reduced sen-
sitivity of target tissues to insulin has become more evident
[1]. Thus, it has been shown that adipocytes secrete biologi-
cally active proteins which profoundly in£uence glucose me-
tabolism. Among those so-called adipocytokines, tumor ne-
crosis factor (TNF) K [2], interleukin-6 (IL-6) [3], and resistin
[4] decrease insulin sensitivity in vivo and in vitro. Recently, it
has been shown that another fat-derived factor, adiponectin,
is an insulin-sensitizing adipocytokine, replenishment of which
increases insulin sensitivity in di¡erent models of insulin re-
sistance in vivo [5,6]. Adiponectin was originally identi¢ed by
four independent groups using di¡erent experimental ap-
proaches and is, therefore, also called Acrp30, GBP28,
apM1, or AdipoQ [7^10]. The protein is a member of the
soluble defense collagen superfamily, and adiponectin expres-
sion is decreased in murine and human obesity and insulin
resistance [9,11,12]. Evidence that adiponectin is not simply a
factor passively regulated by insulin resistance and obesity,
but actively in£uences these states has been presented by dif-
ferent groups [5,6,13,14]. In accordance with adiponectin
being an endogenous insulin sensitizer, various insulin resis-
tance-inducing hormones including insulin, L-adrenergic ago-
nists, glucocorticoids, TNFK, and IL-6 decrease expression of
this adipocytokine in fat cells in vitro [15^17]. Insulin-sensitiz-
ing thiazolidinediones, on the other hand, profoundly stimu-
late adiponectin synthesis in vivo and in vitro [18,19]. Very
recently, two receptors for adiponectin were cloned by Ya-
mauchi et al. and were named adiponectin receptor 1 (Adi-
poR1) and 2 (AdipoR2) [20]. The authors demonstrate that
AdipoR1 is abundantly expressed in skeletal muscle, whereas
AdipoR2 is predominantly found in liver [20]. Until now, it
has not been determined whether adiponectin receptors are
also expressed in adipocytes and might, therefore, potentially
mediate paracrine e¡ects of adiponectin on fat cells. Further-
more, it is tempting to speculate that insulin resistance-induc-
ing hormones might decrease insulin sensitivity at least partly
by downregulating either adiponectin receptor.
In the current study, we therefore studied expression of
adiponectin receptors in 3T3-L1 adipocytes and examined
the e¡ect of di¡erentiation, and major hormones associated
with the regulation of energy balance and insulin resistance
such as insulin, isoproterenol, dexamethasone, triiodothyro-
nine (T3), growth hormone (GH), angiotensin 2 (AT2),
TNFK, and IL-6 on AdipoR1 and AdipoR2 synthesis in vitro.
We demonstrate for the ¢rst time that AdipoR1 and AdipoR2
are expressed in 3T3-L1 adipocytes and are induced during in
vitro di¡erentiation. Furthermore, we provide ¢rst evidence
that GH is a potent, selective, and reversible stimulator of
AdipoR2 synthesis in 3T3-L1 fat cells.
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2. Materials and methods
2.1. Materials
AT2, dexamethasone, GH, IL-6, isobutylmethylxanthine, isoproter-
enol, T3, and TNFK were purchased from Sigma (St. Louis, MO,
USA), insulin from Roche Molecular Biochemicals (Mannheim, Ger-
many). Oligonucleotides were obtained from MWG-Biotech (Ebers-
berg, Germany), cell culture reagents from Life Technologies (Grand
Island, NY, USA).
2.2. Cell culture and di¡erentiation
3T3-L1 preadipocytes (American Type Culture Collection, Rock-
ville, MD, USA) were grown and di¡erentiated into fat cells as pre-
viously described [21]. In brief, cells were grown to con£uence in
Dulbecco’s modi¢ed Eagle’s medium (DMEM) containing 25 mM
glucose, 10% fetal bovine serum (FBS), and antibiotics (culture me-
dium) and con£uent preadipocytes were induced for 3 days in culture
medium further supplemented with 1 WM insulin, 0.5 mM isobutyl-
methylxanthine, and 0.1 WM dexamethasone. Then, they were main-
tained for another 3 days in culture medium with 1 WM insulin and
for an additional 4^8 days in culture medium. After this period, more
than 90% of the cells showed fat droplet accumulation.
2.3. Analysis of AdipoR1 and AdipoR2 gene expression
AdipoR1 and AdipoR2 gene expression was measured by quanti-
tative real-time reverse transcription polymerase chain reaction (RT-
PCR) in a £uorescent temperature cycler (Taqman, Applied Biosys-
tems, Darmstadt, Germany) as described recently [22]. Brie£y, total
RNA was isolated from 3T3-L1 cells using TRIzol (Life Technologies)
and 1 Wg RNA was reverse-transcribed with standard reagents (Life
Technologies). 2 Wl of each RT reaction was ampli¢ed in a 26 Wl PCR
by using the Brilliant SYBR Green QPCR Core Reagent Kit from
Stratagene (La Jolla, CA, USA) according to the manufacturer’s in-
structions. Samples were incubated in the Taqman for an initial de-
naturation at 95‡C for 10 min, followed by 40 PCR cycles, each cycle
consisting of 95‡C for 15 s, 60‡C for 1 min, and 72‡C for 1 min. The
following primers were used: AdipoR1 (accession number BC014875)
CCCCCTTACCCCCGTCCTTAC (sense) and GGCGTGGCTTTG-
TTTGTCCTA (antisense); AdipoR2 (accession number XM_132831)
TGCGCACACGTTTCAGTCTCCT (sense) and TTCTATGATCC-
CCAAAAGTGTGC (antisense); 36B4 (accession number NM007475)
AAGCGCGTCCTGGCATTGTCT (sense) and CCGCAGGGGC-
AGCAGTGGT (antisense). SYBR Green I £uorescence emissions
were monitored after each cycle. Expression of AdipoR1, AdipoR2,
and 36B4 mRNA was quanti¢ed by the second derivative maximum
method of the Taqman Software (Applied Biosystems) determining
the crossing points of individual samples by an algorithm which iden-
ti¢es the ¢rst turning point of the £uorescence curve. AdipoR1 and
AdipoR2 expression was calculated relative to 36B4 which was used
as an internal control due to its resistance to hormonal regulation [23^
25]. Ampli¢cation of speci¢c transcripts was con¢rmed by melting
curve pro¢les (cooling the sample to 68‡C and heating slowly to
95‡C with measurement of £uorescence) at the end of each PCR.
The speci¢city of the PCR was further veri¢ed by subjecting the
ampli¢cation products to agarose gel electrophoresis.
2.4. Statistical analysis
Results are expressed as meanUS.E.M. Di¡erences between treat-
ments were analyzed by unpaired Student’s t-tests. P values 6 0.05
are considered signi¢cant, 6 0.01 highly signi¢cant.
3. Results
3.1. Quanti¢cation of AdipoR1 and AdipoR2 mRNA levels in
3T3-L1 adipocytes
First, the reliability of quantitative real-time RT-PCR was
tested. For this purpose, increasing amounts of total cellular
RNA from di¡erentiated 3T3-L1 cells were reverse-tran-
scribed and analyzed using speci¢c primer pairs for AdipoR1
and AdipoR2 (Fig. 1A,B). Linearity between total RNA used
per reaction and amount of mRNA measured by the Taqman
software was obtained between 2 and 200 ng of total RNA for
both mRNA products (Fig. 1A,B).
3.2. AdipoR1 and AdipoR2 mRNA expression is stimulated
during di¡erentiation
Expression of AdipoR1 and AdipoR2 mRNA during di¡er-
entiation was determined. As compared to undi¡erentiated
preadipocytes, AdipoR1 synthesis increased signi¢cantly 1.4-
fold on day 9 of di¡erentiation (P6 0.01) (Fig. 2A). Induction
of AdipoR2 mRNA expression was more pronounced with a
signi¢cant 3.7- and 4.8-fold stimulation seen on days 6 and 9
of di¡erentiation, respectively, as compared to undi¡erenti-
ated cells (P6 0.01) (Fig. 2B).
3.3. GH stimulates AdipoR2 gene expression in a dose- and
time-dependent manner
To investigate the regulation of AdipoR1 and AdipoR2
Fig. 1. Measurement of AdipoR1 and AdipoR2 mRNA levels in
3T3-L1 adipocytes. Increasing amounts of total RNA from fully dif-
ferentiated 3T3-L1 cells were subjected to quantitative real-time RT-
PCR with primers speci¢c for (A) AdipoR1 and (B) AdipoR2 as de-
scribed in Section 2. Data are expressed relative to mRNA levels
measured with 200 ng RNA (= 100%). Top panels, agarose gel elec-
trophoresis of the PCR products at cycle 28. Furthermore, PCR
products after 40 cycles are shown in samples which were reverse-
transcribed in the presence (+) or absence (3) of RT.
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gene expression in vitro, 3T3-L1 adipocytes were incubated
for 16 h with various hormones which have been shown to
cause insulin resistance and mRNA levels of both receptors
were measured by quantitative RT-PCR. Treatment of 3T3-
L1 cells with 100 nM insulin, 10 WM isoproterenol, 100 nM
dexamethasone, 1 WM T3, 500 ng/ml GH, 10 WM AT2, or
10% FBS did not signi¢cantly in£uence AdipoR1 expression
(Fig. 3A). Furthermore, incubation of di¡erentiated 3T3-L1
cells with insulin (100 nM), isoproterenol (10 WM), GH (500
ng/ml), TNFK (10 ng/ml), and IL-6 (30 ng/ml) for shorter
periods of time did not signi¢cantly in£uence AdipoR1 syn-
thesis (Fig. 3C). A signi¢cant 2.3-fold induction of AdipoR2
expression could be observed when 3T3-L1 adipocytes were
treated with 500 ng/ml GH for 16 h (P6 0.01) (Fig. 3B).
Interestingly, addition of 10% FBS to the starving medium
for 16 h signi¢cantly induced AdipoR2 expression 1.9-fold
(P6 0.01) (Fig. 3B). In contrast, mRNA levels of AdipoR2
were not in£uenced by insulin, isoproterenol, dexamethasone,
T3, AT2, TNFK, and IL-6 (Fig. 3B,D).
GH increased AdipoR2 expression in a dose-dependent
fashion. Thus, signi¢cant 1.9-fold induction of AdipoR2
mRNA was detectable at GH concentrations as low as
5 ng/ml (P6 0.01), and a maximal 2.4-fold increase was found
at 500 ng/ml e¡ector (P6 0.01) (Fig. 4A). Furthermore, Adi-
poR2 gene expression was stimulated in a time-dependent
manner using GH at a concentration of 500 ng/ml (Fig. 4B)
or 50 ng/ml (Fig. 4C). For both conditions, signi¢cant stimu-
lation of AdipoR2 mRNA was ¢rst seen at 2 h of GH addi-
tion with maximal e¡ect observed after 8 h of e¡ector and
induction persisting for up to 24 h (Fig. 4B,C).
3.4. Stimulation of AdipoR2 gene expression by GH is
reversible
Finally, we determined whether the stimulatory e¡ect of
GH on AdipoR2 gene expression was reversible. Fully di¡er-
entiated 3T3-L1 adipocytes were treated with GH (500 ng/ml)
for 16 h and the medium was then replaced by DMEM con-
taining 25 mM glucose and 10% FBS for an additional 24 h.
Addition of GH again increased AdipoR2 mRNA expression
by about 2.4-fold as compared to untreated control cells
(P6 0.01) (Fig. 5, columns 1 and 2). However, removal of
GH from the medium for 24 h decreased AdipoR2 mRNA
expression to control levels (Fig. 5, columns 3 and 4). Inter-
estingly, addition of serum-containing medium for an addi-
tional 24 h again stimulated AdipoR2 gene expression about
1.6-fold (Fig. 5, columns 1 and 3). However, it has to be
pointed out that the decrease in AdipoR2 expression in the
wash-out period after GH treatment (Fig. 5, columns 2 and 4)
and the increase in the wash-in period of the control experi-
ment (Fig. 5, columns 1 and 3) did not reach statistical sig-
ni¢cance.
4. Discussion
Adiponectin is an important adipocytokine with insulin-
sensitizing e¡ects and might represent a novel treatment target
for insulin resistance and type 2 diabetes [5,6]. The mecha-
nisms by which adiponectin decreases insulin resistance have
been better elucidated in recent months. Thus, a globular frag-
ment most potently increases fatty acid combustion in muscle
cells, whereas only full-length adiponectin augments insulin-
induced inhibition of glucose output in liver cells in vivo and
in vitro [5,6,26]. Furthermore, activation of adenosine mono-
phosphate kinase (AMPK) followed by inhibition of acetyl
coenzyme A carboxylase (ACC), as well as stimulation of
peroxisome proliferator-activated receptor K, might be mech-
anisms for the insulin-sensitizing e¡ects of this adipocytokine
[26,27]. Very recently, AdipoR1 and AdipoR2 have been
cloned as two adiponectin receptors [20]. Both proteins are
predicted to contain seven transmembrane domains which
are structurally and functionally distinct from G protein-
coupled receptors [20]. AdipoR1 is preferentially expressed
in muscle and appears as a high-a⁄nity receptor for globular
adiponectin and a low-a⁄nity receptor for full-length adipo-
nectin, whereas AdipoR2 is abundantly found in liver and
serves as an intermediate-a⁄nity receptor for both forms of
adiponectin [20]. In the current study, we show for the ¢rst
time that both adiponectin receptors are also expressed in
3T3-L1 adipocytes and are induced during fat cell di¡erentia-
tion. These ¢ndings imply that adiponectin might alter insulin
sensitivity and metabolism of adipocytes in a paracrine man-
ner besides its well-known e¡ects on muscle and liver cells.
Consistent with this hypothesis, Wu et al. recently demon-
strated activation of AMPK followed by inhibition of ACC
by globular adiponectin in rat adipocytes [28]. Furthermore,
globular adiponectin further enhanced insulin-stimulated glu-
Fig. 2. Di¡erentiation-dependent AdipoR1 and AdipoR2 gene ex-
pression. Con£uent preadipocytes (day 0) were di¡erentiated and on
the indicated days (0, 3, 6, 9) total RNA was subjected to quantita-
tive real-time RT-PCR. AdipoR1 (A) and AdipoR2 (B) mRNA lev-
els are shown relative to cells on day 0 ( = 100%). Results are the
meansUS.E.M. of four independent experiments. **P6 0.01 com-
paring con£uent cells (day 0) with di¡erentiated adipocytes (day 6
and 9). Insets, agarose gel electrophoresis of the PCR products for
(A) AdipoR1 and (B) AdipoR2 at cycle 23.
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cose uptake at submaximal insulin concentrations and re-
versed the inhibitory e¡ect of TNFK on insulin-stimulated
glucose uptake [28].
Various hormones have been shown to induce insulin resis-
tance. However, molecules that mediate these e¡ects are not
well de¢ned. Among those, GH, which is produced primarily
in the anterior pituitary gland as a 22 kDa polypeptide, po-
tently antagonizes insulin action on insulin-sensitive tissues
such as muscle, fat, and liver in vivo and in vitro [29].
Thus, it has been shown that patients with GH excess due
to pituitary tumors are insulin-resistant [30,31]. The role of
GH in common insulin resistance and obesity is less clear. On
the one hand, it has been suggested that nocturnal GH secre-
tion in diabetic patients may contribute to nocturnal hyper-
glycemia [32]. On the other hand, in obese insulin-resistant
individuals basal and stimulated GH secretion are low
[33,34]. In the current study, we demonstrate for the ¢rst
time that AdipoR2 but not AdipoR1 mRNA is potently in-
duced by GH. These ¢ndings indicate that AdipoR2 might be
a mediator of some e¡ects of GH on fat cell metabolism.
Thus, it appears possible that upregulation of AdipoR2 by
GH sensitizes adipocytes to the e¡ects of adiponectin on in-
sulin sensitivity [28]. Since GH has been shown to potently
induce insulin resistance by uncoupling phosphatidylinositol
3-kinase and its downstream signals in 3T3-L1 cells [35], up-
regulation of AdipoR2 might be a compensatory mechanism
by which insulin sensitivity is at least partially restored. Fur-
thermore, the e¡ect of GH on AdipoR2 gene expression is
reversible as removal of the hormone for 24 h decreases Adi-
poR2 mRNA to control levels. Moreover, AdipoR2 is signi¢-
cantly induced by addition of FBS which points to the fact
that GH might also have a strong positive e¡ect in vivo.
However, we cannot exclude the possibility that other, non-
tested hormones present in FBS upregulate AdipoR2 but not
AdipoR1.
Increased serum levels of insulin, catecholamines, glucocor-
ticoids, thyroid hormones, AT2, TNFK, and IL-6 have been
shown to impair glucose tolerance profoundly. On the molec-
ular level, decreased activity of insulin signaling proteins such
as insulin receptor substrate molecules which are essential for
insulin action contributes to insulin resistance induced by
these hormones [36^43]. Furthermore, we and others have
demonstrated that insulin, L-adrenergic agonists, TNFK, and
IL-6 impair insulin sensitivity at least in part by decreasing
adiponectin and stimulating IL-6 expression in fat cells [15^
17,44]. In our in vitro system, insulin, isoproterenol, dexa-
methasone, T3, AT2, TNFK, and IL-6 do not signi¢cantly
a¡ect AdipoR1 and AdipoR2 gene expression. Therefore, it
is unlikely that at least in adipocytes these hormones mediate
their insulin resistance-inducing e¡ects via downregulation of
either receptor.
In summary, we demonstrate for the ¢rst time that Adi-
Fig. 3. Hormonal control of AdipoR1 and AdipoR2 gene expression. Fully di¡erentiated 3T3-L1 adipocytes were (A,B) serum-deprived for 6 h
before insulin (Ins, 100 nM), isoproterenol (Iso, 10 WM), dexamethasone (Dexa, 100 nM), T3 (1 WM), GH (500 ng/ml), AT2 (10 WM), and 10%
FBS were added for 16 h or (C,D) serum-starved overnight before insulin (100 nM), isoproterenol (Iso, 10 WM), TNFK (TNF, 10 ng/ml), IL-6
(30 ng/ml), and GH (500 ng/ml) were added for up to 4 h. Total RNA was subjected to quantitative real-time RT-PCR to determine (A,C)
AdipoR1 and (B,D) AdipoR2 mRNA levels normalized to 36B4 as described in Section 2. Gene expression is shown relative to untreated con-
trol (Co) cells ( = 100%). Results are (A,B) the meansUS.E.M. of at least four and (C,D) the means of at least two independent experiments.
**P6 0.01 comparing GH- and FBS-treated with untreated cells.
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poR1 and AdipoR2 are expressed in 3T3-L1 fat cells and are
upregulated during di¡erentiation of preadipocytes. Further-
more, we show that GH is a highly selective positive regulator
of AdipoR2 but not AdipoR1 synthesis. Further work is
needed to elucidate the role of this regulation for GH-associ-
ated disease states and e¡ects on other insulin-sensitive tissues
such as muscle and liver.
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